Key result
Selective inhibition of ET(A) receptors appears superior to nonselective ERAs in chronic kidney disease, though randomized clinical trials are needed to confirm these findings.
Why the study?
Do selective or nonselective endothelin receptor antagonists have therapeutic potential in chronic kidney disease?
Population
Patients with chronic kidney disease (CKD) and animal models
Design
Review
Authors
Loading...
May support selective ET(A) over nonselective ERAs in CKD; leaves open confirmation in randomized trials.
Do selective or nonselective endothelin receptor antagonists have therapeutic potential in chronic kidney disease?
Selective ET(A) receptor antagonists may offer a superior therapeutic strategy over nonselective ERAs for chronic kidney disease by preserving beneficial ET(B) receptor functions.
Neuhofer et al. (2009) conducted a review in Chronic kidney disease. Endothelin receptor antagonists (ERAs) vs. Nonselective ERAs was evaluated. Selective inhibition of ET(A) receptors appears superior to nonselective ERAs in chronic kidney disease, though randomized clinical trials are needed to confirm these findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: